Under construction – not a live service

Skip to content

Frontlight Research

Institution

Guy's and St Thomas' NHS Foundation Trust

London, United KingdomhealthcareWebsite

98running trials
31closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy
NCT07865364· Source
Not yet recruiting
Metabolism and Nutrition in MND
NCT07851714· Source
Not yet recruiting
How Can the Experience of Hospital Outpatient Departments be Improved?
NCT07818213· Source
Not yet recruiting
Feasibility of Protocolised Analgosedation in ECMO
NCT07580781· Source
Not yet recruiting
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool
NCT07704294· Source
Recruiting
Mechanisms of Atrial Pathoelectrophysiology in HCM
NCT07454135· Source
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154· Phase 1/2· Source
Recruiting
Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction
NCT07560436· Phase 2· Source
Recruiting
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
NCT07235592· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Source
Recruiting
Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds
NCT07386418· Source
Not yet recruiting
Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial
NCT07295834· Phase 2· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Source
Recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
NCT07203768· Source
Recruiting
Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol
NCT07032987· Source
Recruiting
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NCT06887803· Phase 1/2· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Source
Active, not recruiting
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
NCT07260669· Phase 2· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Source
Not yet recruiting
A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure
NCT07084467· Source
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Source
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Source
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Source
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
NCT06843447· Phase 1/2· Source
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884· Phase 2· Source
Active, not recruiting
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
NCT05093231· Phase 2· Source
Recruiting
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
NCT05889312· Source
Active, not recruiting
Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention
NCT07891988· Source
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· Source
Recruiting
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
NCT07363044· Source
Recruiting
Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease
NCT06347536· Phase 3· Source
Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Source
Recruiting
Closed-loop in Adults With Type 2 Diabetes
NCT06579404· Source
Recruiting
Thermotherapy in Addition to SOC Palliative Radiotherapy
NCT06659146· Source
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· Phase 2· Source
Active, not recruiting
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346· Phase 3· Source
Recruiting
Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study
NCT06579443· Source
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· Phase 3· Source
Not yet recruiting
FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion
NCT06416163· Source
Recruiting
Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
NCT06440174· Source
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631· Phase 3· Source
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806· Phase 2· Source
Recruiting
Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung
NCT06144476· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Source
Active, not recruiting
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06023862· Phase 2· Source
Active, not recruiting
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· Phase 3· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers6 recruiting
Lung cancer5 recruiting
COPD4 recruiting
Coronary artery disease4 recruiting
Crohn's disease4 recruiting
Myeloproliferative neoplasms4 recruiting
Melanoma3 recruiting
Head and neck cancer2 recruiting
Heart failure2 recruiting
Hypertrophic cardiomyopathy2 recruiting
Multiple myeloma2 recruiting
Ovarian cancer2 recruiting
Pancreatic cancer2 recruiting
Ulcerative colitis2 recruiting
ALS (motor neurone disease)1 recruiting
ANCA-associated vasculitis1 recruiting
Asthma1 recruiting
Atrial fibrillation1 recruiting
Bladder cancer1 recruiting
Chronic kidney disease1 recruiting
Colorectal cancer1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Follicular lymphoma1 recruiting
Gastric and esophageal cancer1 recruiting
Glaucoma1 recruiting
Haemophilia1 recruiting
High blood pressure1 recruiting
HIV1 recruiting
Huntington's disease1 recruiting
Lupus (SLE)1 recruiting
Metastatic breast cancer1 recruiting
Multiple sclerosis1 recruiting
Neuroendocrine tumours1 recruiting
Neuromyelitis optica (NMOSD)1 recruiting
Pulmonary arterial hypertension1 recruiting
Rheumatoid arthritis1 recruiting
Sickle cell disease1 recruiting
Stroke1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Completed
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
NCT06940154· Phase 2· Source
Completed
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
NCT06940141· Phase 2· Source
Completed
Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma
NCT06364527· Source
Completed
Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder
NCT06251843· Source
Completed
Personalised Cancer Care and Support: Identifying What Good Looks Like
NCT05702684· Source
Completed
AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation
NCT06018545· Source
Terminated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NCT05678257· Phase 2· Source
Terminated
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NCT05714553· Phase 1/2· Source
Terminated
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
NCT06025110· Phase 2· Source
Completed
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
NCT05483933· Phase 1· Source
Completed
Virtual Peer-to-peer Support Programme for Carers of MND
NCT04695210· Source
Completed
Remote Monitoring to Improve Low Adherence in Non-invasive Ventilation
NCT04884165· Source
Completed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127· Phase 2/3· Source
Completed
Realistic Computational Electrophysiology Simulations for the Targetted Treatment of Atrial Fibrillation
NCT05057507· Source
Completed
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
NCT05014412· Phase 2· Source
Completed
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
NCT04776148· Phase 3· Source
Completed
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
NCT04870333· Phase 2/3· Source
Terminated
Hydroxychloroquine in ANCA Vasculitis Evaluation
NCT04316494· Phase 4· Source
Completed
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04362072· Phase 4· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Source
Terminated
Open-Label Extension of Voxelotor
NCT04188509· Phase 3· Source
Completed
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
NCT03979014· Phase 3· Source
Completed
Ustekinumab Real World Evidence Study
NCT07748338· Source
Completed
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
NCT03569293· Phase 3· Source
Completed
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116· Phase 3· Source
Completed
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449· Phase 3· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· Source
Completed
Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
NCT02461888· Phase 2· Source
Completed
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
NCT02308072· Phase 1· Source
Completed
A Study of TAS-120 in Patients With Advanced Solid Tumors
NCT02052778· Phase 1/2· Source
Recruiting
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Heart failure132 works · 2 trials
Asthma73 works · 3 trials
Atrial fibrillation50 works · 2 trials
Psoriasis46 works · 0 trials
Chronic kidney disease44 works · 2 trials
Atopic dermatitis (eczema)42 works · 2 trials
Myeloproliferative neoplasms40 works · 8 trials
Ulcerative colitis36 works · 4 trials
Crohn's disease35 works · 5 trials
Cystic fibrosis35 works · 0 trials
COPD29 works · 6 trials
Coronary artery disease28 works · 6 trials
Type 1 diabetes27 works · 1 trials
Hypertrophic cardiomyopathy23 works · 2 trials
Idiopathic pulmonary fibrosis19 works · 0 trials
Endometrial cancer18 works · 3 trials
Migraine16 works · 1 trials
Psoriatic arthritis11 works · 0 trials
Head and neck cancer11 works · 8 trials
Sickle cell disease10 works · 4 trials
High blood pressure7 works · 1 trials
Spinal muscular atrophy5 works · 0 trials
Familial hypercholesterolaemia4 works · 0 trials

Institution data: ROR 00j161312 (CC0-1.0)Updated 10 Nov 2026

Report an error